How do you review prices for multiple drugs, across multiple markets, instantly?PharmaFootpath is a business intelligence tool for pharmaceutical companies. Bringing together product information, prices, clinical trials, tenders, parallel imports, and more, into a single easy-to-use site.Make smarter decisions. Find new opportunities. Win more business.

At Synamics Therapeutics, our mission is crystal clear: we harness advanced computational and AI/ML techniques to profoundly impact patients' lives. As an end-to-end drug discovery company, we're dedicated to revolutionizing intractable cancer and infectious diseases through AI-powered adaptive drug design.

Prevent target safety failures with unique data insights and cutting-edge approaches. ‍ Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities. Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.

Combine your proprietary omics data with auto-ingested public sources to create bespoke knowledge graphs and in silico cell lines, tissues and patient cohorts.Whether wet or dry lab, access simple query or advanced ML analysis to understand targets, disease biology and mechanisms of action.No-code, collaboration enabled software environment to generate, visualise and share insights at 10X the speed.

•Drug Discovery is hard, and AI and machine learning can help - but only if you're pragmatic and understand both the pitfalls and unique challenges of the industry. The Pharma, Biotech, techbio life sciences are currently undergoing a revolution in data/information generation, and real experience is key to turning this into actionable knowledge •working with multiple startups and early stage companies to develop drug discovery strategies, data strategies, informatics platforms for AI, and/or commercial offerings to pharma clients •evolving SAB and NED activities to further leverage experience and developing funding proposals and pitching strategies

• bringing new AI and machine learning methods together with experienced drug discovery expertise to build out an industry leading portfolio of early research to early clinical phase drug programmes in multiple disease areas with a focus on neuroscience, inflammation/immunology and rare oncology indications•responsible for defining disease selection, establishing therapeutic strategy, new target hypothesis generation and scientific validation of early research programmes for progression to portfolio entry and drug development•leading a diverse multidisciplinary team of scientists with expertise in early drug programme research and applied bioinformatics, with matrix and thought leadership across the whole company on how to apply AI and machine learning to the real practicalities of drug discovery• pragmatic focus on leveraging data and data-driven approaches for drug target identification and validation in neuroscience, immunology/inflammation and oncology indications, with experience in multiple other therapy• translating the drug discovery workflow and hurdles into actionable requirements for software products and informatics platform development• leveraging experience of drug discovery data and data strategy to focus on the real business impact of AI-driven approaches• led the establishment of governance bodies for drug programmes progress, portfolio decisions, scientific strategy, AI product development and overall company drug development strategy• external representation of the company to scientific collaborators, investors, biotech/pharma community • budget management, alliance and collaboration management, CRO and data provider relationships

• Open PHACTS began as an Innovative Medicines Initiative (IMI) project to build a platform for researchers to access and query publicly- available pharmacological data. Together we built the Open PHACTS Discovery Platform by bringing together vast amounts of linked data in a single integrated, open infrastructure• The Open PHACTS Foundation continues to focus on precompetitive drug discovery informatics and data needs to drive constructive and productive collaboration across industry and academia

- OpenPHACTS is an Innovative Medicines Initiative Project IMI http://www.imi.europa.eu/ which in itself is a private partnership between EFPIA and the EU - The OpenPHACTS Vision is to "Create an open knowledge infrastructure enabling facile integration of chemical and biological data to support drug discovery while laying down a long term legacy for service delivery" - OpenPHACTS is part of the IMI Knowledge Management Pillar, and the project is in the final stage of approval and grant agreement prior to funding

Developing the pre-competitive landscape to provide fit-for-purpose computational tools and knowledge management systems. Focus on open innovation models, and collaborative research through existing (Pistoia Alliance, IMI) or future frameworks.Global thought leadership for the application of computational biology to disease knowledge, pathways, networks, biological mechanisms, target identification, potential risk identification.Co-chair of EFPIA Knowledge Management Affinity Group (Jan 2011 onwards) Representing Pfizer at this new forum which aims to: - Define KM challenges & opportunities in collaborative drug discovery & development - Specify informatics systems, components, services and standards needed to enable collaborative drug R&DMember of IMI KM Working Group which aims to execute the IMI Service Infrastructure

Leading the Sandwich Computational Biology line, providing Computational Biology support to the Sandwich Research Units and partner line, innovating systematic strategies for target identification and knowledge management.Representative on global computational science and informatics governance boards for Sandwich, thought leader in the development of new tools and capabilities in the computational sciences space.Active participant in Pistoia Alliance projects, IMI KM project development, EBI Industry Programme.

Active participant representing Pfizer at this important computational science forum

Applying computational biology techniques to exploratory project ideation and progression for the Cardiovascular and Pain Research Units. Contributed to the development the 'Target Knowledge Review' as a project support and learning mechanism, which became used globally within Pfizer.

working in exploratory research on Tissue Repair - wound healing, venous ulcers, scarring, dermatology and ophthalmology. Diverse lab experience from molecular biology to cell biology to enzyme kinetics. Contribute to the development of numerous drug candidates.